Skip to main content

Advertisement

Table 1 Baseline characteristics of participants a

From: An initial loading-dose vitamin D versus placebo after hip fracture surgery: baseline characteristics of a randomized controlled trial (REVITAHIP)

Continuous variables Mean +/- SD
Age in years 83.9+/-7.2
Categorical variables Percentage
Gender (% women) 77.2%
Country of birthc (% Australia) 81.4%
Main language spokenc (% English) 93.5%
Body mass indexd in kg/m2 24.6+/-3.6
Pre-injury living statusc (% at home along) 43.5%
Pre-injury mobilityc (% independent) 69.4%
Pre-injury personal ADLsc (% independent) 64.8%
Pre-injury modified Barthel index 87.09+/-21.04
Pre-injury functional comorbidity index 3.12+/-1.95
Comorbidity present:  
Arthritis 49.1%
Osteoporosis 45.4%
Gastrointestinal 27.4%
Visual impairment 27.3%
Hip fracture subtypee - Undisplaced subcapital: 4.3%
- Displaced subcapital: 46.7%
- Pertrochanteric simple (2-part): 4.3%
- Pertrochanteric complex (3-part): 29.0%
- Intertrochanteric/basicervical: 6.7%
- Subtrochanteric: 9.0%
Hip fracture surgerye - Cannulated screws: 2.4%
- Uncemented hemiarthroplasty: 13.7%
- Cemented hemiarthroplasty: 8.1%
- Total hip replacement: 18.5%
- Dynamic hip screw with short plate: 10.4%
- Dynamic hip screw with long plate: 18.5%
- Gamma nail: 28.4%
MMSE score (c) 26.0+/-4.35
Using calcium (e) 10.4%
Using vitamin D (e) 10.3%
Using other osteoporosis medications (b) 29.9%
Using psychotropic medication (e) 32.7%
Using antihypertensive medication (e) 54.2%
25-hydroxyvitamin D level (f) 52.7+/-23.5 nmol/L
Serum corrected calcium (e) 2.31+/-0.13 mmol/L
Grip strength (e) 16.1+/-6.8 kgs
  1. aAll data are expressed in numbers (% of total) except for continuous variables.
  2. bExcept calcium and vitamin D.
  3. cMissing data = 4 (n=216).
  4. dMissing data = 28 (n=192).
  5. eMissing data = 10 (n=210).
  6. fMissing data = 65 (n=155).